Skip to main content

Table 1 Baseline patient- and disease characteristics by treatment strategy

From: Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

 

All patients (N=213)

Azacitidine (N=26)

Intensive chemotherapy (N=90)

BSC (N=97)

P-value

Overall

Aza vs IC

Age

      

 Median (range)

68 (60–96)

70 (60–81)

66 (60–74)

71 (60–96)

<0.001

<0.001

 ≥ 70 years

80 (38%)

14 (54%)

10 (11%)

56 (58%)

<0.001

<0.001

Sex

    

0.48

0.27

 Male

119 (56%)

17 (65%)

47 (52%)

55 (57%)

Performance score

    

<0.001

0.002

 ≥ 2

121 (59%)

5 (19%)

47 (54%)

69 (75%)

HCT-comorbidity index

    

<0.001

0.029

 Low (0)

98 (46%)

9 (35%)

57 (63%)

32 (33%)

 Intermediate (1–2)

66 (31%)

8 (31%)

18 (20%)

40 (41%)

 High (> 2)

49 (23%)

9 (35%)

15 (17%)

25 (26%)

AML FAB classification

    

0.27

0.28

 M0/M1

41 (20%)

4 (17%)

21 (21%)

16 (19%)

 M2

87 (42%)

8 (33%)

40 (40%)

39 (47%)

 M4/M5

51 (25%)

11 (46%)

22 (22%)

18 (22%)

 M6/M7

13 (6%)

1 (4%)

4 (4%)

8 (10%)

AML type

    

0.089

0.056

 De novo

139 (65%)

13 (50%)

65 (72%)

61 (63%)

 Secondary

74 (35%)

13 (50%)

25 (28%)

36 (37%)

Bone marrow blasts

      

 Median (range)

45 (16–100)

27 (20–88)

52 (20–100)

47 (16–93)

<0.001

<0.001

 ≥ 30%

135 (70%)

11 (42%)

67 (77%)

57 (72%)

0.003

0.001

WBC

      

 Median (range)

5 (0–360)

3 (0–15)

5 (1–236)

7 (1–360)

0.13

<0.001

 ≥ 15 × 109/l

65 (31%)

0 (0%)

31 (34%)

34 (35%)

0.002

<0.001

LDH

      

 Median (range)

324 (116–4835)

259 (136–1133)

340 (134–2664)

332 (116–4835)

0.15

0.092

 > 600 U/l

49 (23%)

2 (8%)

21 (23%)

26 (27%)

0.13

0.15

Cytogenetic risk

    

0.003

0.48

 Favourable

8 (4%)

0 (0%)

4 (4%)

4 (4%)

 Intermediate

135 (63%)

18 (69%)

62 (69%)

55 (57%)

 Unfavourable

47 (22%)

8 (31%)

21 (23%)

18 (19%)

 Not available

23 (11%)

0 (0%)

3 (3%)

20 (21%)

Molecular markers

    

0.27

0.45

 NPMc+/ITD-

13 (7%)

1 (4%)

9 (11%)

3 (4%)

 Others

163 (93%)

23 (96%)

75 (89%)

65 (96%)

  1. Patients with promyelocytic leukaemia (N = 14) were excluded from this analysis. Abbreviations: BSC, best supportive care only; Aza vs IC, azacitidine versus intensive chemotherapy; HCT, hematopoietic cell transplantation; AML, acute myeloid leukaemia; BM, bone marrow; WBC, white blood cell count; LDH, lactate dehydrogenase; NPMc+/ITD-, cytoplasmic NPM1 without FLT3 internal tandem duplication. Results are reported as N (%) unless otherwise indicated.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us